#Sustainability #India #Mumbai #pharmaceutical #Piramal Pharma

Piramal Pharma's FY2026 Annual Report: A Year of Growth and Innovation

Piramal Pharma Limited (PPL), a prominent player in the global pharmaceutical and healthcare sector, has recently released its Annual Report for FY2026. This document emphasizes not only the company's financial successes but also its commitment to sustainability and innovation. Spanning across various international markets, PPL is dedicated to uplifting patient outcomes through scientific advancements and robust operational frameworks.

During the fiscal year, Piramal Pharma reported an impressive revenue of ₹8,869 crore. This achievement can be attributed to its diversified business strategy, underpinned by 17 global development and manufacturing centers and a commercial presence in over 100 countries. Notably, a significant 66% of its revenue stemmed from regulated markets, reflecting the company's strong international position.

Key Highlights from FY2026

One of the standout segments of Piramal Pharma is its Solutions division (CDMO), which generated 55% of total revenues. The division has solidified its role as a leading integrated Contract Development and Manufacturing Organization, serving more than 500 customers in the pharmaceutical and biotechnology fields. In tandem with this growth, Piramal made strategic investments, including a substantial commitment of US$90 million aimed at expanding its sterile injectables and payload linker capabilities.

Moreover, the Piramal Critical Care division has reinforced its dominance in the U.S. inhaled anesthesia category, maintaining its leading position in the Sevoflurane market. The division further expanded its reach through the acquisition of Kenalog, reaching over 6,000 hospitals, surgical centers, and clinics worldwide.

Piramal's Consumer Healthcare branch also performed commendably, posting revenues of ₹1,274 crore. The division launched 31 new products, while its General Brands grew significantly, contributing to over half of the total Consumer Healthcare revenue.

Commitment to Quality

Quality assurance remains a central focus for Piramal Pharma. In FY2026, the company successfully completed 38 regulatory inspections, including three conducted by the U.S. FDA, maintaining a clean slate with zero Official Action Indicated (OAI) observations. This accomplishment underscores Piramal's robust quality control systems and adherence to compliance protocols.

Focus on Sustainability

Piramal Pharma is making strides in its sustainability initiatives, having achieved a 22.6% reduction in Scope 1 and Scope 2 greenhouse gas emissions since FY2022, thanks to its scientifically-backed decarbonization roadmap. This commitment to environmental responsibility aligns with broader industry trends toward sustainability in healthcare.

Additionally, Piramal has cultivated a people-first culture, employing over 7,285 individuals globally. The company holds a strong commitment to workplace safety, marking five consecutive years without any fatalities.

Looking Ahead

Chairperson Nandini Piramal mentioned that FY2026 was a pivotal year, shaped by various external disruptions but ending on a positive note. The company is now geared up for future growth across its business segments, with optimism fueled by strategic initiatives and improved execution pathways.

As Piramal Pharma continues to navigate the complexities of the global pharmaceutical landscape, it remains focused on harnessing innovative science, operational excellence, and sustainable practices. For further insights and performance metrics, the detailed FY2026 report is accessible through their official website.

For more information, visit Piramal Pharma.